Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,440,320
  • Shares Outstanding, K 82,010
  • Annual Sales, $ 179,580 K
  • Annual Income, $ -61,680 K
  • 36-Month Beta 1.56
  • Price/Sales 19.20
  • Price/Cash Flow N/A
  • Price/Book 5.61

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.74 +4.07%
on 12/15/17
49.25 -13.91%
on 11/21/17
-2.65 (-5.88%)
since 11/15/17
3-Month
40.74 +4.07%
on 12/15/17
60.15 -29.51%
on 10/04/17
-10.00 (-19.08%)
since 09/15/17
52-Week
19.25 +120.26%
on 12/22/16
60.15 -29.51%
on 10/04/17
+21.25 (+100.47%)
since 12/15/16

Most Recent Stories

More News
This Morning's Research Reports on Biotechnology Stocks -- FibroGen, Global Blood Therapeutics, Intercept Pharma, and Nektar Therapeutics

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on FGEN, GBT, ICPT, and NKTR which is a click away at www.wallstequities.com/registration....

GBT : 36.25 (-7.99%)
FGEN : 42.40 (+1.07%)
ICPT : 61.62 (+0.02%)
NKTR : 56.90 (+3.36%)
Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU

Desk Line-up: FibroGen Post Earnings Coverage

FGEN : 42.40 (+1.07%)
PLX : 0.61 (-1.45%)
Featured Company News - FDA Approved Teligent's Betamethasone Dipropionate Ointment USP (Augmented), 0.05%

Research Desk Line-up: FibroGen Post Earnings Coverage

TLGT : 3.92 (+1.82%)
FGEN : 42.40 (+1.07%)
FibroGen, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / FibroGen, Inc. (NASDAQ: FGEN) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 5:00 PM Eastern Time.

FGEN : 42.40 (+1.07%)
FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017

FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the third quarter of 2017 on Wednesday, November 8, 2017, after market...

FGEN : 42.40 (+1.07%)
FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)

FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd. (FibroGen China), today announced that the China Food...

FGEN : 42.40 (+1.07%)
FibroGen Appoints Gerald Lema to Board of Directors

FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Gerald Lema, former President of Asia Pacific at Baxter International, has been appointed to the Company's...

BAX : 65.33 (+0.85%)
FGEN : 42.40 (+1.07%)
Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017

FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today positive results from the company's Phase 2b randomized, double-blind, placebo-controlled study (Study 067) in patients...

FGEN : 42.40 (+1.07%)
FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017

FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF monoclonal antibody in late-stage development for the...

FGEN : 42.40 (+1.07%)
Fibrogen Inc Has Returned 83.2% Since SmarTrend Recommendation (FGEN)

SmarTrend identified an Uptrend for Fibrogen Inc (NASDAQ:FGEN) on February 17th, 2017 at $24.34. In approximately 6 months, Fibrogen Inc has returned 83.17% as of today's recent price of $44.58.

FGEN : 42.40 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

2nd Resistance Point 44.97
1st Resistance Point 43.69
Last Price 42.40
1st Support Level 40.93
2nd Support Level 39.45

See More

52-Week High 60.15
Fibonacci 61.8% 44.53
Last Price 42.40
Fibonacci 50% 39.70
Fibonacci 38.2% 34.87
52-Week Low 19.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.